US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Provectus Biopharmaceuticals, Inc.

0.0474

+0.00245.33%

Volume:351.85K

Turnover:16.28K

Market Cap:19.92M

PE:-2.99

High:0.0474

Open:0.0450

Low:0.0450

Close:0.0450

52wk High:0.1130

52wk Low:0.0380

Shares:420.28M

Float Shares:386.66M

Volume Ratio:0.93

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0159

EPS(LYR):-0.0213

ROE:22.69%

ROA:-623.13%

PB:-3.23

PE(LYR):-2.22

Loading ...

Overview Company News Filings

Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028

Provectus announces publication of preclinical research on PV-10

BRIEF-Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral Pv-10 in Bladder Cancer

THOMSON REUTERS

Provectus Q2 Sales $57.480K Down From $254.991K YoY

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PVCT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PVCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVCT\",,,,,undefined,":{"symbol":"PVCT","market":"US","secType":"STK","nameCN":"Provectus Biopharmaceuticals, Inc.","latestPrice":0.0474,"timestamp":1771016296667,"preClose":0.045,"halted":0,"volume":351852,"delay":15,"changeRate":0.05333333333333332,"floatShares":386656900,"shares":420279879,"eps":-0.015852,"marketStatus":"Post-Mkt","change":0.0024,"latestTime":"02-13 15:58:16 EST Delay","open":0.045,"high":0.0474,"low":0.045,"amount":16276.443999999998,"amplitude":0.053333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.015852,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771030800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.045,"volumeRatio":0.928862},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVCT\",,,,,undefined,":{"symbol":"PVCT","floatShares":386656900,"roa":"-623.13%","roe":"22.69%","lyrEps":-0.021324,"volumeRatio":0.928862,"shares":420279879,"dividePrice":0,"high":0.0474,"amplitude":0.053333,"preClose":0.045,"low":0.045,"week52Low":0.038,"pbRate":"-3.23","psRate":"56.85","week52High":0.113,"institutionHeld":0.0006,"latestPrice":0.0474,"eps":-0.015852,"divideRate":0,"volume":351852,"delay":15,"ttmEps":-0.015852,"open":0.045,"prevYearClose":0.0559,"prevWeekClose":0.0384,"prevMonthClose":0.051,"prevQuarterClose":0.0559,"fiveDayClose":0.0384,"twentyDayClose":0.0572,"sixtyDayClose":0.061},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVCT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-08-13","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-14","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-03-28","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-22","symbol":"PVCT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1708578000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVCT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVCT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608889761","title":"Provectus Biopharmaceuticals verlängert automatisches Umwandlungsdatum für Vorzugsaktien bis 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889761","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608889761?lang=en_us&edition=fundamental","pubTime":"2026-02-03 04:31","pubTimestamp":1770064263,"startTime":"0","endTime":"0","summary":"Provectus Biopharmaceuticals Inc. hat angekündigt, dass der Stichtag für die automatische Umwandlung der Series D und Series D-1 Convertible Preferred Stock in Stammaktien vom 20. Juni 2026 auf den 31. Dezember 2028 verschoben wird. Die nderungen wurden vom Vorstand sowie einem ausschlielich aus unabhngigen Mitgliedern bestehenden Sonderausschuss genehmigt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL7Crx4q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT","BK4007"],"gpt_icon":0},{"id":"2574942152","title":"Provectus announces publication of preclinical research on PV-10","url":"https://stock-news.laohu8.com/highlight/detail?id=2574942152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574942152?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:20","pubTimestamp":1760012424,"startTime":"0","endTime":"0","summary":"Provectus (PVCT) Biopharmaceuticals announced the publication of independent preclinical research by Aru Narendran, MD, PhD and colleagues at the U...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/provectus-announces-publication-of-preclinical-research-on-pv-10-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/provectus-announces-publication-of-preclinical-research-on-pv-10-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVCT","BK4007"],"gpt_icon":0},{"id":"2571733337","title":"BRIEF-Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10","url":"https://stock-news.laohu8.com/highlight/detail?id=2571733337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571733337?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:10","pubTimestamp":1759147806,"startTime":"0","endTime":"0","summary":"BRIEF-Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10Sept 29 (Reuters) - Provectus Biopharmaceuticals Inc PVCT.PK:PROVECTUS BIOPHARMACEUTICALS INITIATES PRECLINICAL STUDY OF ORA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA1WTCV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT","BK4007"],"gpt_icon":0},{"id":"2571338574","title":"Provectus Biopharmaceuticals Initiates Preclinical Study of Oral Pv-10 in Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2571338574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571338574?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:00","pubTimestamp":1759147201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUA1WTCV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVCT","BK4007"],"gpt_icon":0},{"id":"2559676189","title":"Provectus Q2 Sales $57.480K Down From $254.991K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2559676189","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559676189?lang=en_us&edition=fundamental","pubTime":"2025-08-15 05:53","pubTimestamp":1755208385,"startTime":"0","endTime":"0","summary":"Provectus (OTC:PVCT) reported $57.480 thousand in sales this quarter. This is a 77.46 percent decrease over sales of $254.991 thousand the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47143187/provectus-q2-sales-57-480k-down-from-254-991k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Provectus Q2 Sales $57.480K Down From $254.991K YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVCT"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}